可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]Ong P,Athanasiadis A,Borgulya G,et al.High prevalence of a pathological response to acetylcholine testing in patients with stable anginapectoris and unobstructed coronary arteries. The ACOVA Study(Abnormal COronary VAsomotionin patients with stable angina and unobstructed coronary arteries)[J].J Am Coll Cardiol,2012,59(7):655-662.
[2]Sara JD,Widmer RJ,Matsuzawa Y,et al.Prevalence of Coronary Microvascular Dysfunction Among Patients With Chest Pain and NonobstructiveCoronary Artery Disease[J].JACC Cardiovasc Interv,2015,(11):1445-1453.
[3]Melikian N,Vercauteren S,Fearon WF,et al.Quantitative assessment of coronary microvascular function in patients with and without epicardial atherosclerosis[J].EuroIntervention,2010,5(8):939-945.
[4] Berger JS,Elliott L,Gallup D,et al.Sex differences in mortality following acute coronary syndromes[J].JAMA,2009,302(8):874-882.
[5]Park GM,Lee SW,Cho YR,et al.Coronary computed tomographic angiographic findings in asymptomatic patients with type 2 diabetes mellitus[J].Am J Cardiol,2014,113(5):765-771.
[6]van den Hoogen IJ,de Graaf MA,Roos CJ,et al.Prognostic value of coronary computed tomography angiography in diabetic patients without chest pain syndrome[J].J Nucl Cardiol,2016,23(1):24-36.
[7]Young LH,Wackers FJ,Chyun DA,et al.Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes:the DIAD study:a randomized controlled trial[J].JAMA,2009,301(15):1547-1555.
[8]Eskerud I,Gerdts E,Nordrehaug JE,et al.Global Coronary Artery Plaque Area is Associated with Myocardial Hypoperfusion in Women with Non-STElevation Myocardial Infarction[J].J Womens Health(Larchmt),2015,24(5):367-373.
[9]Pijls NH,Fearon WF,Tonino PA,et al.Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease:2-year follow-up of the FAME(Fractional Flow Reserve Versus Angiography for Multivessel Evaluation)study[J].J Am Coll Cardiol,2010,56(3):177-184.
[10]De Bruyne B,Pijls NH,Kalesan B,et al.Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease[J].N Engl J Med,2012,367(11):991-1001.
[11]Curzen N,Rana O,Nicholas Z,et al.Does routine pressure wire assessment influence management strategy at coronary angiography for diagnosis of chest pain?:The RIPCORD study[J].Circ Cardiovasc Interv,2014,7(2):248-255.
[12]Herrmann J,Kaski JC,Lerman A.Coronary microvascular dysfunction in the clinical setting:from mystery to reality[J].Eur Heart J,2012,33(22):2771-2782.
[13]Sen T.Coronary Slow Flow Phenomenon Leads to ST Elevation Myocardial Infarction[J].Korean Circ J,2013,43(3):196-198.
[14]Xu Y,Meng HL,Su YM,et al.Serum YKL-40 is increased in patients with slow coronary flow[J].Coron Artery Dis,2015,26(2):121-125.
[15]Dogan M,Akyel A,Cimen T,et al.Relationship between neutrophil to lymphocyte ratio and slow coronary flow[J].Clin Appl Thromb Hemost,2013,21(3):251-254.
[16]Akboga MK,Canpolat U,Balci KG,et al.Increased Platelet to Lymphocyte Ratio is Related to Slow Coronary Flow[J].Angiology,2016,67(1):21-26.
[17]Badimon L,Vilahur G.Thrombosis formation on atherosclerotic lesions and plaque rupture[J].J Intern Med,2014,276(6):618-632.
[18]Rana A,Goyal N,Ahlawat A,et al.Mechanisms involved in attenuated cardio-protective role of ischemic preconditioning in metabolic disorders[J].Perfusion,2015,30(2):94-105.
[19]Maslov LN,Naryzhnaya NV,Pei JM,et al.Problem of end-effector of ischemic postconditioning of the heart[J].Ross Fiziol Zh Im I M Sechenova,2015,101(6):647-669.
[20]Thomas RL,Gustafsson AB.Mitochondrial autophagy--an essential quality control mechanism for myocardial homeostasis[J].Circ J,2013,77(10):2449-2454.
[21]Wojciechowska M,Zarebiński M,Pawluczuk P,et al.Decreased effectiveness of ischemic heart preconditioning in the state of chronic inflammation[J].Med Hypotheses,2015,85(5):675-679.
[22]Chytilová A,Borchert GH,Mandíková-Alánová P,et al.Tumour necrosis factor-α contributes to improved cardiac ischaemic tolerance in rats adapted to chroniccontinuous hypoxia[J].Acta Physiol(Oxf),2015,214(1):97-108.
[23]Arbab-Zadeh A,Nakano M,Virmani R,et al.Acute coronary events[J].Circulation,2012,125(9):1147-1156.
[24]Dong L,Mintz GS,Witzenbichler B,et al.Comparison of plaque characteristics in narrowings with ST-elevation myocardial infarction(STEMI),non-STEMI/unstable angina pectoris and stable coronary artery disease(from the ADAPT-DES IVUS Substudy)[J].Am J Cardiol,2015,115(7):860-866.
[25]Kubo T,Maehara A,Mintz GS,et al.The dynamic nature of coronary artery lesion morphology assessed by serial virtual histology intravascular ultrasound tissue characterization[J].J Am Coll Cardiol,2010,55(15):1590-1597.
[26]Di Vito L,Prati F,Arbustini E,et al.A“stable”coronary plaque rupture documented by repeated OCT studies[J].JACC Cardiovasc Imaging,2013,6(7):835-836.
[27]Yonetsu T,Kakuta T,Lee T,et al.In vivo critical fibrous cap thickness for rupture-prone coronary plaques assessed by optical coherence tomography[J].Eur Heart J,2011,32(10):1251-1259.
[28]Stone GW,Maehara A,Lansky AJ,et al.A prospective natural-history study of coronary atherosclerosis[J].N Engl J Med,2011,364(3):226-235.
[29]Stergiopoulos K,Boden WE,Hartigan P,et al.Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease andmyocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials[J].JAMA Intern Med,2014,174(2):232-240.
[30]Zimmermann FM,Ferrara A,Johnson NP,et al.Deferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis:15-year follow-up of the DEFER trial[J].Eur Heart J,2015,36(45):3182-3188.
[31]Lautam?ki A,Airaksinen KE,Kiviniemi T,et al.Prognosis and disease progression in patients under 50 years old undergoing PCI:the CRAS(Coronary aRterydiseAse in younG adultS)study[J].Atherosclerosis,2014,235(2):483-487.
[32]Fach A,Bünger S,Zabrocki R,et al.Comparison of Outcomes of Patients With ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention Analyzed by Age Groups(<75, 75 to 85, and >85 Years);(Results from the Bremen STEMI Registry)[J].Am J Cardiol,2015,116(12):1802-1809.
[33]Shaw LJ,Berman DS,Maron DJ,et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: resultsfrom the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclearsubstudy[J].Circulation,2008,117(10):1283-1291.
[34]Fihn SD,Gardin JM,Abrams J,et al.2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management ofpatients with stable ischemic heart disease: executive summary:a report of the American College of Cardiology Foundation/American Heart Association task force on practiceguidelines, and the American College of Physicians,American Association for ThoracicSurgery,Preventive Cardiovascular Nurses Association,Society for CardiovascularAngiography and Interventions,and Society of Thoracic Surgeons[J].Circulation,2012,126(25):3097-3137.